SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Denham JW. How do we bring an acceptable level of radiotherapy services to a dispersed population? Australas Radiol. 1995; 39: 171173.
  • 2
    Barton MB. Radiotherapy utilisation in New South Wales from 1996 to 1998. Australas Radiol. 2000; 44: 483484.
  • 3
    Lote K, Moller T, Nordman E, et al. Resources and productivity in radiation oncology in Denmark, Finland, Iceland, Norway and Sweden during 1987. Acta Oncol. 1991; 30: 555561.
  • 4
    Mackillop WJ, Dixon P, Zhou Y, et al. Variations in the management and outcome of non-small cell lung cancer in Ontario. Radiother Oncol. 1994; 32: 105115.
  • 5
    Foroudi F, Tyldesley S, Walker H, Mackillop WJ. An evidence-based estimate of appropriate radiotherapy utilization rate for breast cancer. Int J Radiat Oncol Biol Phys. 2002; 53: 12401253.
  • 6
    Delaney G, Barton B, Jacob S. Estimation of an optimal radiotherapy utilization rate for breast cancer: a review of the evidence. Cancer. 2003; 98: 19771986.
  • 7
    Delaney G, Barton M, Jacob S, Jalaludin B. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol. 2003; 4: 120128.
  • 8
    Tyldesley S, Boyd C, Shulze K, Walker H, Mackillop WJ. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys. 2001; 49: 973985.
  • 9
    Foroudi F, Tyldesley S, Barbera L, Huang J, Mackillop WJ. An evidence-based estimate of the appropriate radiotherapy utilization rate for colorectal cancer. Int J Radiat Oncol Biol Phys. 2003; 56: 12951307.
  • 10
    Foroudi F, Tyldesley S, Barbera L, Huang J, Mackillop WJ. Evidence-based estimate of appropriate radiotherapy utilization rate for prostate cancer. Int J Radiat Oncol Biol Phys. 2003; 55: 5163.
  • 11
    Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR). Cancer in Australia 1998. Canberra: AIHW, 2001.
  • 12
    National Health and Medical Research Council. Clinical practice guidelines for the management of cutaneous melanoma. Available from URL: http://www.health.gov.au/nhmrc/publications/pdf/cp68.pdf. Updated 1999. [accessed April 6, 2003.]
  • 13
    National Comprehensive Cancer Network. Clinical practice guidelines in oncology, vol 1. Melanoma. Available from URL: http://www.nccn.org/physician_gls/f_guidelines.html. Updated 2002. [accessed April 6, 2003.]
  • 14
    National Cancer Institute. PDQ cancer information summaries: treatment of melanoma. Available from URL: http://www.cancer.gov/cancerinfo/pdq/treatment/melanoma/healthprofessional. Updated 2003. [accessed April 6, 2003].
  • 15
    European School of Oncology START State of the Art Oncology in Europe. Melanoma treatment guidelines. Available from URL: http://www.startoncology.net/viewStart.asp?Id=32. Updated 2003. [accessed April 6, 2003.]
  • 16
    National Health and Medical Research Council. Guide to the development, implementation and evaluation of clinical practice guidelines. Appendix B. Canberra: National Health and Medical Research Council, 1998: 56.
  • 17
    Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1989; 95: 2S4S.
  • 18
    SA Cancer Registry. Epidemiology of cancer in South Australia. September, 2000 (cancer series no. 22). Adelaide: South Australian Cancer Registry, 2000.
  • 19
    O'Brien CJ, Coates AS, Petersen-Schaefer K, et al. Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg. 1991; 162: 310313.
  • 20
    Slingluff CL. Surgical management of regional lymph nodes in patients with melanoma. Ann Surg. 1994; 219: 120130.
  • 21
    Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, et al. Metastatic patterns, clinical outcome and malignant phenotype in malignant cutaneous melanoma. Acta Oncol. 1999; 38: 549557.
  • 22
    Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on cancer melanoma staging system. J Clin Oncol. 2001; 19: 36223634.
  • 23
    Calabro A, Singletary E, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg. 1989; 124: 10511055.
  • 24
    Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with Stage I or II melanoma. J Clin Oncol. 1998; 16: 22532260.
  • 25
    Geara FB, Ang KK. Radiation therapy for malignant melanoma. Surg Clin North Am. 1996; 76: 13831398.
  • 26
    Miller EJ, Daly JM, Synnestvedt M, Schultz D, Elder D, Guerry D. Loco-regional nodal relapse in melanoma. Surg Oncol. 1992; 1: 333340.
  • 27
    Ang KK, Peters LJ, Weber RS, et al. Post-operative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys. 1994; 30: 795798.
  • 28
    Stevens G, Thompson JF, Firth I, O'Brien CJ, McCarthy WH, Quinn MJ. Locally advanced melanoma. Results of postoperative hypofractionated radiation therapy. Cancer. 2000; 88: 8894.
  • 29
    Burmeister BH, Smithers BM, Poulsen M, et al. Radiation therapy for nodal disease in malignant melanoma. World J Surg. 1995; 19: 369371.
  • 30
    Corry J, Smith JG, Bishop M, Ainslie J. Nodal radiation therapy for metastatic melanoma. Int J Radiat Oncol Biol Phys. 1999; 44: 10651069.
  • 31
    Cancer Statistics Branch, National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) Program public-use CD-ROM (1973–1997). Bethesda: National Cancer Institute, 2000.
  • 32
    American College of Surgeons. National Cancer Database. Available from URL: http://www.facs.org.dept/cancer/ncdb/whatsncdb.html. Updated 2003. [accessed April 6, 2002.]
  • 33
    Statewide Services Development Branch. NSW radiotherapy management information system report 2000. Sydney: NSW Health Department, 2001.